Kyowa Hakko IMS Company Profile

Publication Date	December 2007
Publisher	IMS Health
Product Type	Report
Pages	56
ISBN Number	not applicable
Product Code	IMS00018

Buy this product or for assistance call +44 20 7060 7474

PDF £249.00$414 | €279

CD-ROM £249.00$414 | €279

FAX Order above formats by FAX

Summary

IMS Health's Company Profiles give you the authoritative insight into a company at a strategic and local level.

Each individual IMS Company Profile analyzes the critical components that make up a pharmaceutical company, providing you with a clear assessment of the relative strengths and weaknesses of a company's business strategy.

Critical analyses provided by an in-house expert team
90+ full in-depth company profiles covering all major pharmaceutical companies worldwide
Generic, Biotechnology and Drug Delivery companies
Includes IMS Health sales data on products and therapies
In depth product and R&D reviews, including clinical trial, lifecycle management, competition and analysts forecasts
Mergers and acquisitions; licensing agreements
Forecasts and comments from leading financial analysts
Companies' conferences, annual reports, press releases
Comments from stockbrokers/analysts reports used throughout the profile and especially within the Strategy, Financial and Product sections.

Content

Corporate Structure
Strategy statement
Highlights a company's strengths / weaknesses and its potential for future growth. The strategy analysis gives you an insight into the following:
- M&A
- Regional strategies
- Therapeutic focus
- R&D strategy
- Licensing activities
- Commentary on future prospects, including brokers' overviews
- Interview with a key person (where available), including quotes and opinions
- Forecasting table (top 30 companies only), showing events with major potential impact
Financial Review
Company sales performance as well as analyst's comments and forecasts.
Company Sales Performance:
- Financial review
- Latest results
- Sales by geographical region & leading country
- Sales by country and subsidiary
- Analysis comments
Product Portfolio
Company Profiles reviews up to 40 products per company, whilst annual reports from the top 10 pharmaceutical companies cover up to a maximum of 10 drugs.
The section shows:
- Summary table of products facing patent expiry.
- Breakdown by relevant therapy area, within which, each product is discussed under the following headings: general, licensing, patents, clinical data, lifecycle management, competition and analysts' forecasts/comments.
R&D Pipelines
Comprehensive details of the projects that the company has in its R&D pipeline including:
- Research pipeline summary table.
- Introduction to the R&D activities of the company.
- Breakdown by relevant therapy area, within which, each project is detailed (up to 2 A4 pages), including information on clinical status and analysts' forecasts.
- Quotes from senior personnel gleaned from conferences may also be included in this section when available.
Key figures
- Sales by business segment.
- Sales by geographical region.
Analyst figures
IMS sales data
- Pharmaceutical sales by geographical region and leading countries.
- Top 5 third level therapeutic classes.
- Leading international products
- Pharmaceutical sales analysis by age
Employee data
Licensing/Co-Marketing Agreements
Displayed in a tabular format to enable you to have "at a glance" review of the licensing activities of the company.
Three sections are available to review licensing activities:
- Marketed products
- R&D pipeline products
- General research collaborations, including combinatorial chemistry, proprietary technologies etc.
Major Events
Summary of the major events that have affected the company. This includes recent and historical events.
Two sections
- Mergers and Acquisitions
- Other major events
Events are organised in chronological order.
Subsidiaries listing
Mini-profile of each subsidiary that the company has worldwide showing address, major contacts and principal products.
Other IMS Company Profiles